Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer.

AIM To evaluate diffusion-weighted magnetic resonance imaging (DW-MRI) as a marker for disease aggressiveness by comparing tumour apparent diffusion coefficients (ADCs) between patients with low- versus higher-risk localized prostate cancer. METHOD Forty-four consecutive patients classified as low- [n = 26, stageT1/T2a, Gleason score < or = 6, prostate-specific antigen (PSA)< 10 (group 1)] or intermediate/high- [n = 18, stage > or = T2b and/or Gleason score > or = 7, and/or PSA > 10 (group 2)] risk, who subsequently were monitored with active surveillance or started neoadjuvant hormone and radiotherapy, respectively, underwent endorectal MRI. T2-weighted (T2W) and DW images (5 b values, 0-800 s/mm(2)) were acquired and isotropic ADC maps generated. Regions of interest (ROIs) on T2W axial images [around whole prostate, central gland (CG), and tumour] were transferred to ADC maps. Tumour, CG, and peripheral zone (PZ = whole prostate minus CG and tumour) ADCs (fast component from b = 0-100 s/mm(2), slow component from b = 100-800 s/mm(2)) were compared. RESULTS T2W-defined tumour volume medians, and quartiles were 1.2 cm(3), 0.7 and 3.3 cm(3) (group 1); and 6 cm(3), 1.3 and 16.5 cm(3) (group 2). There were significant differences in both ADC(fast) (1778 +/- 264 x 10(-6) versus 1583 +/- 283 x 10(-6) mm(2)/s, p = 0.03) and ADC(slow) (1379 +/- 321 x 10(-6) versus 1196 +/- 158 x 10(-6) mm(2)/s, p = 0.001) between groups. Tumour volume (p = 0.002) and ADC(slow) (p = 0.005) were significant differentiators of risk group. CONCLUSION Significant differences in tumour ADCs exist between patients with low-risk, and those with higher-risk localized prostate cancer. DW-MRI merits further study with respect to clinical outcomes.

[1]  H. Huisman,et al.  Standardized Threshold Approach Using Three-Dimensional Proton Magnetic Resonance Spectroscopic Imaging in Prostate Cancer Localization of the Entire Prostate , 2007, Investigative radiology.

[2]  A Semjonow,et al.  Implementation of a map in radical prostatectomy specimen allows visual estimation of tumor volume. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  T. Hirai,et al.  Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. , 2006, AJNR. American journal of neuroradiology.

[4]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[5]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[6]  Jun Nakashima,et al.  Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. , 2004, Urology.

[7]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[8]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[9]  Sharyn I. Katz,et al.  MR imaging and MR spectroscopy in prostate cancer management. , 2006, Radiologic clinics of North America.

[10]  V. Pansadoro,et al.  Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 2004, La Radiologia medica.

[11]  A. Amorosi,et al.  Estimation of Prostate Cancer Volume by Endorectal Coil Magnetic Resonance Imaging vs. Pathologic Volume , 1999, European Urology.

[12]  P. Carroll,et al.  Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. , 2004, Radiology.

[13]  A. Hanlon,et al.  A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[14]  Michael W Kattan,et al.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B K Rutt,et al.  Quantitative diffusion imaging in implanted human breast tumors , 1997, Magnetic resonance in medicine.

[16]  J. Kurhanewicz,et al.  Magnetic Resonance Imaging and Spectroscopic Imaging of Prostate Cancer , 2001, Cancer investigation.

[17]  J R Thornbury,et al.  Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. , 1996, AJR. American journal of roentgenology.

[18]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[19]  P. Grant,et al.  Diffusion MR imaging. Theory and applications. , 1999, Neuroimaging clinics of North America.

[20]  Silvia D. Chang,et al.  Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology , 2006, Journal of magnetic resonance imaging : JMRI.

[21]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[22]  A G Sorensen,et al.  Diffusion-weighted MR imaging in acute stroke: theoretic considerations and clinical applications. , 1999, AJR. American journal of roentgenology.

[23]  N. deSouza,et al.  MAGNETIC RESONANCE IMAGING IN PROSTATE CANCER : VALUE OF APPARENT DIFFUSION COEFFICIENTS FOR IDENTIFYING MALIGNANT NODULES , 2010 .

[24]  M. Kattan,et al.  Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. , 2006, Radiology.

[25]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[26]  R. Mason,et al.  Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. , 2003, Neoplasia.

[27]  Olivier Rouvière,et al.  Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? , 2007, European Radiology.

[28]  P. Walsh.  Adult Urology: Urological Survey: Urologic Oncology: Prostate CancerProstate Cancer Localization With Endorectal MR Imaging and MR Spectroscopic Imaging: Effect of Clinical Data on Reader Accuracy , 2005 .

[29]  Usha Sinha,et al.  Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.

[30]  Takeo Ishigaki,et al.  Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. , 2007, European journal of radiology.

[31]  Cher Heng Tan,et al.  Diffusion weighted imaging in prostate cancer , 2011, European Radiology.

[32]  Clare Allen,et al.  How good is MRI at detecting and characterising cancer within the prostate? , 2006, European urology.

[33]  C. Ling,et al.  Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Reiser,et al.  Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology. , 2007, AJR. American journal of roentgenology.

[35]  B. Issa,et al.  In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo‐planar imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[36]  R. Gillies,et al.  Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. , 1999, Neoplasia.

[37]  D. Dearnaley,et al.  Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[38]  Peter Gibbs,et al.  Comparison of quantitative T2 mapping and diffusion‐weighted imaging in the normal and pathologic prostate , 2001, Magnetic resonance in medicine.

[39]  Evis Sala,et al.  Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. , 2006, Radiology.

[40]  R. Kauppinen,et al.  Water diffusion in a rat glioma during ganciclovir‐thymidine kinase gene therapy‐induced programmed cell death in vivo: Correlation with cell density , 2004, Journal of magnetic resonance imaging : JMRI.

[41]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[42]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[43]  Viraj A Master,et al.  The independent impact of extended pattern biopsy on prostate cancer stage migration. , 2005, The Journal of urology.

[44]  Nancy Wells,et al.  Tumour volume is an independent predictor of prostate‐specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer , 2006, BJU international.

[45]  C. Beaulieu,et al.  Diffusion-weighted magnetic resonance imaging: theory and potential applications to child neurology. , 1999, Seminars in pediatric neurology.

[46]  Stefan A Reinsberg,et al.  Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. , 2007, AJR. American journal of roentgenology.